About the SELECT trial SELECT was a randomised, double-blind, parallel-group, placebo-controlled trial designed to evaluate the efficacy of Wegovy (semaglutide 2.4 mg) versus placebo as an adjunct to standard of care for the prevention of MACE in people with overweight or obesity and established CVD with no prior history of diabetes
More than one-third of participants receiving Ozempic (semaglutide) lost more than 20% of their weight
As long-term longitudinal studies play out, sometimes new impacts are found
Although our cerebral GSH results do not support the redox hypothesis of autism in the brain, previous results of decreased GSH in the plasma of autistic children may help explain some other inflammatory symptoms that autistic children experience (e.g
doi: 10.1007/s10238-022-00799-z 146 Thomaides-BrearsHBAlkhouriNAllendeDHarisinghaniMNoureddinMReauNSet al
International Journal of Clinical Pharmacy , 46 (2), 488495